title: Cerebrolysin inhibits lipid peroxidation induced by insulin hypoglycemia in the brain and heart of mice.
abstract: As a consequence of enhanced production of oxygen free radicals, lipid peroxidation leads to the degradation of membrane lipids and disturbances of membrane permeability. Lipid peroxidation increases under stress conditions such as hypoxia, ischemia or acidosis as well as in metabolic diseases, e.g. diabetes mellitus. We have shown that subcomatous doses of insulin (6.0 IU/kg) significantly increase thiobarbituric acid reactive substances (TBARs), especially malondialdehyde (MDA) - the endproduct of lipid peroxidation, in the brain and heart of mice. In our model of insulin-induced hypoglycemia, mice were treated with the neuroprotective, peptide-containing drug Cerebrolysin (100 mg/kg b.w.). Animals were sacrificed by decapitation two or three hours after the injection of tested substance and samples were taken to determine several serum parameters (glucose, total protein, triglycerides and lactic acid) and TBARs in the brain and heart. Although Cerebrolysin was not able to affect serum parameters after subcomatous insulin injection, the drug significantly influenced lipid peroxidation. A single injection of Cerebrolysin already decreased TBARs levels in the brain and heart tissue. Presuming that an increase of TBARs reflects disturbances of the cell membrane, we have documented a promising effect of Cerebrolysin on cell integrity.
authors.affiliation: Department of Pharmacology, Third Faculty of Medicine, Charles University, Ruská 87, 100 00 Prague 10, Czech Republic. Jitka.Patockova@lf3.cuni.cz
authors.forename: J
authors.initials: J
authors.lastname: Patocková
authors.forename: M
authors.initials: M
authors.lastname: Krsiak
authors.forename: P
authors.initials: P
authors.lastname: Marhol
authors.forename: E
authors.initials: E
authors.lastname: Tůmová
mesh_terms: D000596:Amino Acids / Q000494:pharmacology*; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001798:Blood Proteins / Q000378:metabolism; D001923:Brain Chemistry / Q000187:drug effects*; D006321:Heart / Q000187:drug effects; D007003:Hypoglycemia / Q000097:blood* / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007328:Insulin / Q000494:pharmacology*; D019344:Lactic Acid / Q000097:blood; D015227:Lipid Peroxidation / Q000187:drug effects*; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009206:Myocardium / Q000378:metabolism*; D018696:Neuroprotective Agents / Q000494:pharmacology*; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D014280:Triglycerides / Q000097:blood
chemical_list: D000596:Amino Acids; D001786:Blood Glucose; D001798:Blood Proteins; D007004:Hypoglycemic Agents; D007328:Insulin; D018696:Neuroprotective Agents; D017392:Thiobarbituric Acid Reactive Substances; D014280:Triglycerides; D019344:Lactic Acid; C006952:cerebrolysin